Increased expression of CAV-1 is linked to the minor allele A [69], and reduced expression of CAV-1 can influence aldosterone and mineralocorticoid receptor signaling in various pathways connected to glycemia and dyslipidemia [70, 71]. Here, NR3C2 is linked to metabolic syndrome.